ACHC — Acadia Healthcare Company, Inc.

Acadia Healthcare (ACHC) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: $851.6 million, up 4.4% year-over-year.
• Adjusted EBITDA: $173 million, down from $194.3 million in Q3 2024, reflecting lower-than-expected volumes and increased expenses.
• Same-Facility Volume Growth: 1.3%, below internal expectations by approximately 100 basis points.
• Adjusted EPS Guidance: Revised to $2.35 - $2.45 from $2.45 - $2.65.
• Net Leverage Ratio: Approximately 3.4x.
• CapEx for Q3: $135.8 million, favorable compared to plans.

2. Strategic Updates and Business Highlights

• Leadership Changes: Todd Young appointed as CFO, succeeding Tim Sides, who transitions to Senior VP of Operations, Finance. Dr. Nasser Khan steps down as COO but will assist as an advisor.
• Growth Initiatives: Over 1,700 beds added in 2024 and 2025, with plans for an additional 500 to 700 beds in 2026. Focus on optimizing existing facilities and enhancing patient care through technology investments.
• Quality Improvements: Implementation of a quality dashboard with over 50 KPIs to enhance operational excellence and payer engagement.
• Facility Closures: Five facilities closed due to underperformance, with a focus on optimizing the portfolio for better returns.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Revised to $3.28 billion - $3.3 billion from $3.3 billion - $3.35 billion.
• Adjusted EBITDA Guidance: Reduced to $650 million - $660 million from $675 million - $700 million.
• 2026 Outlook: Anticipated reduction in startup losses and ramp-up from new beds, with a focus on disciplined growth and capital allocation. Specific guidance to be provided in February 2026.

4. Bad News, Challenges, or Points of Concern

• Volume Pressures: Softer-than-expected volumes, particularly in Medicaid, leading to increased scrutiny on length of stay and higher denial rates.
• Increased Expenses: Rising costs associated with employee healthcare and professional liability expenses, contributing to the downward revision of EBITDA guidance.
• Legal Expenses: $39 million incurred in Q3 related to ongoing investigations, although expected to decline moving forward.
• Payer Relations: Ongoing challenges with Medicaid reimbursement and increased denials impacting revenue and profitability.

5. Notable Q&A Insights

• Payer Challenges: Management acknowledged ongoing friction with payers, particularly in Medicaid, with increased scrutiny on discharge criteria and length of stay.
• Q4 Expectations: Caution advised against using Q4 as a run-rate for 2026 due to seasonal trends and expected reductions in startup losses.
• CapEx Strategy: A $300 million reduction in CapEx for 2026, focusing on high-return projects and pausing lower-return developments.
• Supplemental Payments: Potential for $22 million in Medicaid supplemental payments, with uncertainty around timing due to government operations.
• Future Growth: Management remains optimistic about growth opportunities, particularly with new bed additions and quality improvements, despite current headwinds.

This summary encapsulates the key elements from Acadia Healthcare's Q3 2025 earnings call, highlighting both the company's performance and the challenges it faces moving forward.